Pharma Equity Group’s Subsidiary Receives a Notification from the EPO Regarding the “Intention to Grant” for Patents of the Subsidiary’s Wound-Healing Drug Combination and the Treatment of Colorectal Cancer.

By
Jamie Kang
-
0
82
Pharma Equity Group’s subsidiary, Reponex Pharmaceuticals, announced that the European Patent Office has issued an “Intention To Grant” for EU patent applications numbers 15724673.7 and 19701467.3.
[Pharma Equity Group A/S]
Press Release